maturation inhibitor

maturation inhibitor

An antiretroviral agent that inhibits viral replication by disrupting late Gag processing, which is required for the structural rearrangement of viral maturation, a key step in the maturation of viral particles into mature, infectious virions.

Maturation inhibitors (e.g., PA-457) prevent virus maturation by interrupting the conversion of the capsid precursor (p25) to a mature capsid protein (p24), resulting in the formation of defective, noninfectious virus particles.
Mentioned in ?
References in periodicals archive ?
The second late stage asset is a maturation inhibitor (BMS-955176), and is currently in phase IIb development for both treatment-naive and treatment experienced patients.
A back-up maturation inhibitor candidate (BMS-986173) is also included in the purchase.
The Bristol-Myers Squibb clinical stage HIV pipeline reportedly includes an attachment inhibitor (BMS-663068) that is being investigated in Phase III as a therapeutic option for heavily treatment-experienced patients as well as a maturation inhibitor (BMS-955176) that is being investigated in Phase IIb development for treatment-naive and treatment-experienced patients.
Other maturation-preventing factors in follicular fluid are oocyte maturation inhibitor (57) and hypoxanthine, (58) which acts only in combination with cAMP.
Results with this new 'first-in-class' maturation inhibitor have been encouraging; it is well tolerated, has favourable pharmacokinetics, a long half-life [20,25] and little potential for drug interactions [24].
Food and Drug Administration for the company's second-generation HIV maturation inhibitor, PA-1050040.
released results of a small, 10-day human trial of the maturation inhibitor PA-457, the first time more than a single dose of this compound has been tested in HIV-positive people.
The second late stage asset is a maturation inhibitor (BMS-955176), currently in phase IIb development for both treatment-naive and treatment experienced patients.
Bevirimat (Panacos Pharmaceuticals) is an HIV maturation inhibitor.
The third-generation maturation inhibitor program has compounds that are chemically distinct from bevirimat and have activity against polymorphic HIV.
Bevirimat, a first-in-class maturation inhibitor discovered by Panacos' scientists and their academic collaborators, is one of Panacos' several antiviral assets.
These actions are being taken to manage capital resources while Panacos pursues strategic alternatives, including the financing, partnering or sale of the Company or one of its several antiviral assets, including bevirimat (PA-457), the Company's first-in-class maturation inhibitor, which is currently in Phase 2b clinical studies in HIV-positive patients, the next-generation maturation inhibitor program (consisting of second- and third-generation compounds) and the oral fusion program (consisting of its lead compound, PA-161).